Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 485.00
Bid: 480.00
Ask: 490.00
Change: -5.00 (-1.02%)
Spread: 10.00 (2.083%)
Open: 490.00
High: 490.00
Low: 485.00
Prev. Close: 490.00
SYS1 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Industry Award Winner

20 Sep 2007 07:02

BrainJuicer Group PLC20 September 2007 Press Release 20 September 2007 BrainJuicer Group PLC ("BrainJuicer" or "the Company") Winner of Best Methodology at ESOMAR BrainJuicer Group PLC, (AIM: BJU), a leading international online marketresearch agency, today announces that it has been awarded the prize for BestMethodology paper at this year's annual ESOMAR Congress for the Company's newFaceTraceTM product. FaceTraceTM was launched earlier in 2007, and is currently being used by anumber of BrainJuicer's blue chip clients, including Unilever, Shell, Pepsi, andProcter & Gamble. This product offers a new method of measuring emotionalengagement, based on Ekman's research into the way emotions are conveyed andunderstood via the face. Panellists are shown photographs of faces illustratingvarious emotions, and asked to select the one which best represents theirreaction to the product that is being tested. The next stage is to ascertain thedegree to which the emotion is felt, and then explore the reasons behind thereaction. FaceTraceTM is the key tool in the Company's new advertising screeningproduct, as well as being used in collaboration with a number of existingproducts; this further enhances the qualitative depth of research whichBrainJuicer is able to offer its clients. ESOMAR is the global market research association, and its annual Congress thisyear was attended by 1,300 people. There were 170 submissions from all over theworld, 40 selected to be presented at the Congress, and three short listed forprizes in each of the three categories; Best Methodology, Best Case Study andBest Overall Paper. The Best Methodology award is given to the paper of mosttechnical and innovative interest, which adds significant value to the toolsavailable to researchers. BrainJuicer won the Best Methodology Paper prize in 2005 for the Company'sproduct Predictive Markets; this award today makes BrainJuicer the only agencyto win twice in over 20 years. John Kearon, CEO of BrainJuicer, commented: "We are delighted that this new andinnovative product has been recognised by the industry. It validates the strongwork of the team and demonstrates our ability to add value to the researchprocess for our clients. "The fact that we are the only agency to have won this paper twice in over 20years is also a great achievement for the team, as it illustrates howsignificant an impact our products have made on the industry." - Ends - For further information, please contact:BrainJuicer plc John Kearon, Chief Executive Officer Tel: +44 (0)20 7043 1000 www.brainjuicer.com Landsbanki Securities (UK) LimitedFred Walsh / Simon Brown Tel: +44 (0)20 7426 9000 www.landsbanki.co.uk Media enquiries:Abchurch CommunicationsHeather Salmond / Joanne Shears Tel: +44 (0) 20 7398 7700joanne.shears@abchurch-group.com www.abchurch-group.com Notes to Editors: BrainJuicer carries out quantitative online research using innovative, bespokesoftware to produce insightful market research for large, multinationalcompanies, including 10 of the world's top 50 companies (FT 500 September 2006). BrainJuicer operates in a growing sector of the US$25bn global research market,namely quantitative online research. BrainJuicer's main competitors are largetraditional market research providers who have dominated the market for off-linemarket research, such as AC Nielsen, Millward Brown, Research International andTaylor Nelson Sofres. Whilst the largest traditional research companies have developed their ownonline capability, BrainJuicer has a number of key attributes which havecontributed to it achieving rapid growth and winning contracts with prestigiousclients, including: • Research platform that delivers greater diagnostic insight. BrainJuicer hasdeveloped tools and award-winning techniques that enable it to provide a greaterlevel of diagnostic insight into quantitative market research. These techniquesenable clients to enhance their understanding of consumer preference and helpthem make decisions on the best way to develop their products and services. • Speed. BrainJuicer's automated research techniques enable it to conductcomplicated studies very quickly. BrainJuicer's rapid deployment and resultsproduction, even on multi-country studies, provide clients with a speed tomarket advantage in the development of new products and services. • A scaleable online-only business model. Unlike the traditional researchcompanies who maintain both on and offline data collection capabilities,BrainJuicer is able to focus on operating a scaleable online-only businessmodel. To date the Group has conducted projects in over 50 countries and more than 30languages and has established offices in the UK, the Netherlands and the US. The Group's revenues come from full service market research work, and from itsonline Juicy Brains Panel in the UK. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th Apr 20247:00 amRNSTrading Update
24th Jan 20247:00 amRNSTrading Update
12th Dec 202312:51 pmRNSPresentation via Investor Meet Company
6th Dec 20237:00 amRNSChange of Auditor
6th Dec 20237:00 amRNSInterim Results
24th Oct 20237:00 amRNSTrading Update
27th Sep 20236:00 pmRNSResult of AGM
27th Sep 20237:00 amRNSTrading Update
31st Aug 20237:00 amRNSAnnual Report and Notice of AGM
1st Aug 20237:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2023
31st Jul 20232:00 pmRNSPreliminary Results Presentation
13th Jul 20237:30 amRNSTrading update
30th Jun 20239:00 amRNSResolution of Complaint for Trademark Infringement
28th Jun 202311:00 amRNSHolding(s) in Company
3rd May 20233:15 pmRNSFurther re Result of General Meeting
21st Apr 202311:56 amRNSResult of General Meeting
13th Apr 20237:00 amRNSFurther re Requisitioned General Meeting
12th Apr 20237:00 amRNSTrading Update
5th Apr 202310:45 amRNSNotice of Trading Update
24th Mar 20234:00 pmRNSPosting of Circular and Notice of Requisitioned GM
24th Mar 20237:00 amRNSPosting of Circular and Notice of Requisitioned GM
7th Mar 20237:30 amRNSReceipt of Requisition Notice
28th Feb 202312:50 pmRNSCapital Markets Day
23rd Feb 20237:00 amRNSTrading Update
14th Feb 20237:00 amRNSCapital Markets Day
13th Jan 20232:00 pmRNSDirector/PDMR Shareholding
10th Jan 202310:30 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSDirector/PDMR Shareholding
14th Dec 20224:00 pmRNSDirector/PDMR Shareholding
13th Dec 20226:25 pmRNSDirector/PDMR Shareholding
6th Dec 20224:15 pmRNSDirectorate Change
30th Nov 20227:00 amRNSInterim Results
25th Oct 20227:00 amRNSTrading Update
28th Sep 20226:15 pmRNSResult of AGM
31st Aug 202211:00 amRNSNotice of AGM
31st Aug 20227:00 amRNSDirectorate Change
31st Aug 20227:00 amRNSReview of strategic options
30th Aug 20226:00 pmRNSTransaction in Own Shares
19th Aug 20228:55 amRNSTransaction in Own Shares
3rd Aug 20225:45 pmRNSTransaction in Own Shares
2nd Aug 20223:45 pmRNSTransaction in Own Shares
29th Jul 20229:30 amRNSTransaction in Own Shares
26th Jul 20226:24 pmRNSTransaction in Own Shares
19th Jul 20224:00 pmRNSHolding(s) in Company
19th Jul 20223:00 pmRNSTransaction in Own Shares
18th Jul 20224:30 pmRNSTransaction in Own Shares
15th Jul 20225:15 pmRNSTransaction in Own Shares
12th Jul 20227:00 amRNSShare Buyback Programme
12th Jul 20227:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2022
12th Jul 20227:00 amRNSQuarterly Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.